Table 1

Variables evaluated in the univariate analysis for the different endpoints examined

			Stage 4
	MT	TT	p Value	CPA≥6%	CPA≥7.2%	HVPG≥10 mm Hg	Decompensation
Cold/warm ischaemia time (min)	680/46	688/41	NS	NS	NS	NS	NS
Treatment allocation (evaluated)	54 (49)	49 (48)	<0.001	<0.001	<0.001	<0.001	<0.001
Stopped azathioprine	NA	16 (33%)	<0.001	<0.001	<0.001	0.012	0.013
Tacrolimus trough concentrations (ng/mL)
5 days	7.7	5	0.002	0.002	0.01	0.017	0.01
15 days*	8.5	6.1	0.003	0.001	0.01	0.001	0.01
30 days*	7.9	6.7	0.01	0.01	0.04	0.02	0.01
Conc. HCC	17	13	NS	NS	NS	NS	0.03
Conc. ALD	10	12	NS	NS	NS	NS	NS
Age	48.9 years	50 years	NS	NS	NS	NS	NS
Donor age	48.5 years	44 years	0.01	0.01	0.01	0.04	0.02
Gender mismatch	17	17	NS	NS	NS	NS	NS
Rejection episodes	42	64	0.002	0.0033	0.04	0.033	NS
Rejection treatment (courses)	21	30	0.002	0.01	0.03	0.038	NS
HDNH	17	8	<0.001	<0.001	<0.001	<0.001	<0.001
CMV viraemia treated	7	10	NS	NS	NS	NS	NS
Viral load logIU/mL (median)
Pre-LT	5.29	5.36	NS	NS	NS	NS	NS
3 m post-LT	6.6	6.39	NS	NS	NS	NS	NS
Genotype 1/1b	41%	41%	NS	NS	NS	NS	NS
Antiviral treatment	19	11	0.01	0.01	0.01	0.001	0.001
SVR	3	3	NS	NA	NA	NA	NA
DM
Pre-LT	13	13	NS	NS	NS	NS	NS
Post-LT (last follow-up)	19	15	0.013	0.038	0.044	NS	NS

*Median trough levels derived from all measurements up to days 15 and 30 post-LT.
ALD, alcoholic liver disease; CMV, cytomegalovirus; CPA, collagen proportionate area; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HDNH, histological de novo hepatitis; HVPG, hepatic venous pressure gradient; LT, liver transplantation; MT, monotherapy; NA, non-applicable; NS, non-significant; SVR, sustained virological response; TT, triple therapy.